Navigation Links
SuperGen Reports 2008 Third Quarter Financial Results
Date:11/4/2008

Royalty Revenue Increases 67% from Same Prior Year Period

DUBLIN, Calif., Nov. 4 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced financial results for the third quarter and nine months ended September 30, 2008.

Total revenues for the 2008 third quarter were $10.2 million compared with $6.1 million for the same prior year period. Total revenues for the 2008 third quarter and same prior year period consist entirely of royalty revenue. Royalty revenue is earned pursuant to the license agreement entered into with MGI PHARMA (acquired by Eisai Co., Ltd. in January 2008) during 2004, which granted the licensee exclusive rights to the development, manufacture, commercialization and distribution of Dacogen(R) (decitabine) for Injection. The Company recognizes royalty revenue on a cash basis when it is received.

Excluding gain on sale of products, total costs and operating expenses for the 2008 third quarter were $11.4 million, compared with $9.2 million for the same prior year period. The primary reason for the increase in total costs and operating expenses for the 2008 third quarter were higher research and development costs related to increased product development activities including ongoing clinical operations and the payment of additional severance costs in the amount of $98,000 related to the closure of our European operations offset in part by a reduction in general and administrative expenses related to the cessation of our European operations and lower stock-based compensation expense. The closure of the European operations was effective October 1, 2008 and is anticipated will reduce future ope
'/>"/>

SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
4. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
5. SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008
6. SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
7. SuperGen Reports 2008 First Quarter Financial Results
8. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
9. SuperGen Reports 2008 Second Quarter Financial Results
10. SuperGen to Present at Merriman 5th Annual Investor Summit on September 15, 2008
11. SuperGen to Present Data at EORTC-NCI-AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... and REHOVOT, Israel , August ... medical 3D printing specialist, Replica 3DM, supports NHS hospitals with ... Printers   - Performing surgery on ... anesthetic times; improves patient recovery and provides an effective aid ... Stratasys Ltd. (Nasdaq: SSYS ), a global ...
(Date:8/26/2014)... , Aug. 26, 2014   Lycera Corp ... breakthrough oral medicines to treat autoimmune disease and ... today announced the appointment of Harinder Singh ... advisory board.  Dr. Singh will lead the board,s ... Lycera,s multiple ongoing research programs and pipeline of ...
(Date:8/26/2014)... Vycom announced today that Modutek Corporation ... equipment, has selected its Flametec materials for a ... Beams (FRIB). This involved the creation of a ... Flametec PVC-C and Kytec PVDF material to clean superconducting ... linear accelerator (known as LINAC). , ...
(Date:8/26/2014)...   Loveland Products, a subsidiary of Agrium and ... products and proprietary products provider for Agrium Retail ... a controlling interest in Agricen, a ... products for efficient and sustainable plant nutrition. Agricen ... nutrition brands, Accomplish ® LM and Titan ...
Breaking Biology Technology:Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 2Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 3Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 5Lycera Appoints Harinder Singh, Ph.D., as Chair of Scientific Advisory Board 2Lycera Appoints Harinder Singh, Ph.D., as Chair of Scientific Advisory Board 3Modutek Selects Vycom’s Flametec Materials for Michigan State University’s Superconductor Equipment 2Modutek Selects Vycom’s Flametec Materials for Michigan State University’s Superconductor Equipment 3Agrium, through Loveland Products, Acquires a Controlling Interest in Agricultural Biotechnology Company Agricen 2Agrium, through Loveland Products, Acquires a Controlling Interest in Agricultural Biotechnology Company Agricen 3Agrium, through Loveland Products, Acquires a Controlling Interest in Agricultural Biotechnology Company Agricen 4
... from a chimp? Researchers from the European Molecular ... one important step closer to answering such evolutionary ... Science they uncover systematic errors in existing ... to learn about their evolutionary relationships. They present ...
... JumpStart Inc., the Northeast Ohio,venture development ... businesses and ideas, has announced an investment ... The JumpStart,investment is part of a recently ... RMS Management of Cleveland, OH., (Logo: ...
... EMERYVILLE, Calif., June 19 Onyx,Pharmaceuticals, Inc. (Nasdaq: ... present,at the Jefferies 2nd Annual Healthcare Conference on ... parties may access a live webcast of,the presentation ... It is recommended that listeners log on ...
Cached Biology Technology:Scientists fix bugs in our understanding of evolution 2JumpStart Invests in Tursiop Technologies 2JumpStart Invests in Tursiop Technologies 3
(Date:8/27/2014)... what is described by the Volunteer Wildfire Services of ... Cape provincial government warned residents in certain parts of ... veld fires. A high veld fire danger rating ... coast in the Great Kei and Mnquma area. ... thunderstorms. The thunderstorms bring lightning strikes and subsequent ...
(Date:8/27/2014)... consumers are willing to pay a premium for fruits, ... getting what the label claims is another matter. Now ... new way to make sure farms are labelling their ... Journal of Agricultural and Food Chemistry , could help ... Health and Food Safety Authority and the Wuerzburg University ...
(Date:8/27/2014)... studies have shown that excessive iron is ... disease. Previous studies from Chunyan Guo and ... have shown that baicalin prevented iron accumulation ... transporter 1 expression, and increased ferroportin 1 ... Parkinson,s disease rats. However, the relationship between ...
Breaking Biology News(10 mins):
... hope a vaccine is on the horizon for tularemia, a ... an organism of concern as a potential biological warfare agent. ... according to the August issue of the Journal of ... and rapid progress has been made in understanding how it ...
... in a new 5,000-square-foot exhibition, "Dig it! The Secrets ... D.C. The exhibition will travel to museums across the ... experts, along with the President of the Soil Science ... the new "Dig It! The Secrets of Soil" exhibition, ...
... research published in the July issue of the Journal ... DNA is a reliable marker of recurrent esophageal cancer. The ... evidence of cancer recurrence in the majority of patients. ... cancer death worldwide, is usually diagnosed at a late stage. ...
Cached Biology News:Francisella tularensis: Stopping a biological weapon 2Plasma DNA level is a reliable marker of recurrent esophageal cancer, study finds 2
ELISpot kit for human Granzyme B. Kits contain PVDF plates, capture & detection antibodies, streptavidin-ALP, BSA, Skimmed dry milk, BCIP/NTB substrate, and wash buffer...
Request Info...
Applications: (+) Immunocytochemistry and immunohistochemistry...
RABBIT ANTI WARFARIN...
Biology Products: